Home › Core › ISCC-IDs › 28CrXSS8TFjoP

View ISCC-ID

Core Data

28CrXSS8TFjoP
ISCC-ID - digital asset identifier
CCf3eK8tTqttj-CTdrqAVxR2h4P-CDrQnjGGLAheC-CRV8aXsQVywsV
ISCC-CODE - digital asset descriptor
2QTa5N4aeSrCB2MLoPdPF4AsTjstJgcLTnd
PUBLIC-KEY or WALLET-ADDRESS of DECLARING PARTY
0
Number of times updated

Seed Metadata (Immutable)

regulation of major histocompatibility class ii gene expression in frtl5 thyrocytes opposite effects of interferon and methimazo

Ledger Reference

coblo
Source Ledger/Blockchain
538453
N-th ISCC Decleration on source ledger
78b3e3f0afce225daaa4c336d35d82eb5662933f567fb66c0f9ec6f372de190f
Hash of block that includes the ISCC-DECLARATION
b1426a50477aed3ae68ff8f461ed0b1ed9e8157988a9db241666dcbce866138c
Hash of transaction that includes the ISCC-DECLERATION
0
Output index that includes ISCC-DECLERATION (UTXO based chains)

Mutable Metadata

[{"data": {"name": "Regulation of Major Histocompatibility Class II Gene Expression in FRTL-5 Thyrocytes: Opposite Effects of Interferon and Methimazole", "@type": "ScholarlyArticle", "genre": "journal-article", "author": [{"name": "V. Montani", "@type": "Person"}], "@context": "http://schema.org/", "encoding": [{"@type": "MediaObject", "contentUrl": "https://academic.oup.com/endo/article-pdf/139/1/290/10351486/endo0290.pdf", "encodingFormat": "application/pdf"}], "publisher": {"name": "The Endocrine Society", "@type": "Organization"}, "identifier": [{"@type": "PropertyValue", "value": "10.1210/en.139.1.290", "propertyID": "DOI"}, {"@type": "PropertyValue", "value": "CCf3eK8tTqttj-CTdrqAVxR2h4P-CDrQnjGGLAheC-CRV8aXsQVywsV", "propertyID": "ISCC"}], "datePublished": "1998-01-01"}, "schema": "schema.org", "mediatype": "application/ld+json"}]
Close